Patients with advanced heart failure often remain severely symptomatic and have a high mortality rate despite currently available therapy. We studied the safety and efficacy of a new approach to the patient with refractory heart failure: continuous intravenous treatment via a portable infusion pump with epoprostenol (prostacyclin), a potent pulmonary and systemic vasodilator. A group of 33 patients with severe heart failure (64% New York Heart Association class IV and 36% class III) and profound ventricular dysfunction (median left ventricular ejection fraction, 0.15)-despite prior treatment with diuretics (100%), digitalis (91%), angiotensin-converting enzyme inhibitors (85%), and dobutamine (30%)-underwent a baseline 6-minute walk test prior to dose titration with epoprostenol during invasive hemodynamic monitoring. Subjects responding during the dose titration were randomized, on an open basis, to receive either continuous epoprostenol infusion via an indwelling central venous catheter plus conventional therapy or conventional therapy alone for 12 weeks. The initial dose-ranging study with epoprostenol produced a significant decline in systemic and pulmonary vascular resistance and a substantial increase in cardiac index despite a fall in pulmonary capillary wedge pressure. Symptoms related to vasodilation were noted within the first week after randomization to epoprostenol in 9 of 16 patients but resolved with adjustment of the infusion and concomitant medications in all but one subject. Dose adjustments during the chronic epoprostenol infusion were infrequent after the first week and complications related to the drug delivery system were rare. The change in distance walked from baseline to the last available 6-minute walk test was significantly greater in patients who received epoprostenol compared with patients assigned to standard therapy (72 ± 40 vs -39 ± 32 m, mean ±SEM; p = 0.033). Our study suggests that longterm intravenous infusion of epoprostenol is feasible in patients with severe heart failure and our hemodynamic and functional results suggest clinical benefit as well. However, until recent results indicating an adverse effect of epoprostenol on survival are fully evaluated, the role of this drug in the treatment of advanced heart failure will remain uncertain.
|Original language||English (US)|
|Journal||The American Journal of Cardiology|
|Issue number||3 SUPPL. 1|
|State||Published - Jan 19 1995|
Bibliographical noteFunding Information:
Health Sciences Center, University of Arizona, Tucson, Arizona substantial morbidity and mortality in these pa-Research Triangle Park (S.H.G., J.W.C., C.L.S., M.D.T.). This (S.M.B.); Division of Clinical Research, Burroughs Wellcome Co., tients. Epoprostenol, a naturally occurring metabo-study was supported by a grant from Burroughs Wellcome Co., lite of arachidonic acid,4 has physiologic actions as Research Triangle Park, North Carolina. delineated by Dzau et al5 that may benefit patients Address for reprints: Carla A. Sueta, whose severe heart failure persists despite aggres-7075, Burnett-Womack Building, Chapel Cardiology, University of North Carolina sive conventional therapy. In contrast to most 27.599-7075. available vasodilators, this prostaglandin is a po-